Detalhe da pesquisa
1.
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
N Engl J Med
; 390(6): 497-509, 2024 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38324483
2.
A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply.
N Engl J Med
; 390(17): 1632-1633, 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38692302
3.
Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life.
Clin Gastroenterol Hepatol
; 20(6): 1354-1361.e7, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34329774
4.
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet
; 394(10213): 2012-2024, 2019 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31727409
5.
The effect of testosterone on ovulatory function in transmasculine individuals.
Am J Obstet Gynecol
; 223(2): 229.e1-229.e8, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32044312
6.
Protein tyrosine phosphatase of liver regeneration-1 is required for normal timing of cell cycle progression during liver regeneration.
Am J Physiol Gastrointest Liver Physiol
; 308(2): G85-91, 2015 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25377314
7.
Discovery of camphor-derived pyrazolones as 11ß-hydroxysteroid dehydrogenase type 1 inhibitors.
Bioorg Med Chem Lett
; 24(12): 2707-11, 2014 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24815509
8.
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis.
Aliment Pharmacol Ther
; 59(1): 51-63, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37786277
9.
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.
Nat Med
; 29(11): 2919-2928, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37845512
10.
Discovery and optimization of 2-phenyloxazole derivatives as diacylglycerol acyltransferase-1 inhibitors.
Bioorg Med Chem Lett
; 21(23): 7205-9, 2011 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22001092
11.
Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH.
Hepatol Commun
; 5(4): 573-588, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33860116
12.
Sugar binding to recombinant wild-type and mutant glucokinase monitored by kinetic measurement and tryptophan fluorescence.
Biochem J
; 413(2): 269-80, 2008 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18370929
13.
Potent, selective MCH-1 receptor antagonists.
Bioorg Med Chem Lett
; 18(4): 1402-6, 2008 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18243691
14.
The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy.
Diabetes
; 55(1): 1-12, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16380470
15.
A glucose sensor role for glucokinase in anterior pituitary cells.
Diabetes
; 55(7): 1923-9, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16804059
16.
From clinicogenetic studies of maturity-onset diabetes of the young to unraveling complex mechanisms of glucokinase regulation.
Diabetes
; 55(6): 1713-22, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16731834
17.
Hepatoprotection via the IL-6/Stat3 pathway.
J Clin Invest
; 112(7): 978-80, 2003 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-14523032
18.
Massive hepatic apoptosis associated with TGF-beta1 activation after Fas ligand treatment of IGF binding protein-1-deficient mice.
J Clin Invest
; 111(1): 129-39, 2003 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-12511596
19.
Impaired hepatocyte DNA synthetic response posthepatectomy in insulin-like growth factor binding protein 1-deficient mice with defects in C/EBP beta and mitogen-activated protein kinase/extracellular signal-regulated kinase regulation.
Mol Cell Biol
; 23(4): 1251-9, 2003 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-12556485
20.
Cervical mucus and contraception: what we know and what we don't.
Contraception
; 96(5): 310-321, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28801053